DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity.
Saved in:
| Title: | DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. |
|---|---|
| Authors: | Stockmann AP; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Vincent S; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Herschelman L; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Huang CS; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Ma J; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Fallon D; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Kirby P; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Gutierrez E; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Talbot D; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Hicks SW; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Wagtmann N; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA., Cheung AF; Dragonfly Therapeutics, Inc., Waltham, MA 02451, USA. Electronic address: ann.cheung@dragonflytx.com. |
| Source: | Cell reports. Medicine [Cell Rep Med] 2026 Jan 20; Vol. 7 (1), pp. 102518. Date of Electronic Publication: 2025 Dec 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
